Regeneron Pharmaceuticals

Most active this month

• Dell Technologies1044 filings
• CrowdStrike269 filings
• Seagate Technology213 filings
• DDODatadog134 filings
• eBay Inc.111 filings
• Alphabet102 filings

• A securities lawsuit naming the company as a defendant was filed on Sep 23, 2026 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

  Hopkinson v. Regeneron Pharmaceuticals, Inc., 7:26-cv-08311

• A securities lawsuit naming the company as a defendant was filed on Jul 16, 2026 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

  Cheatham v. Regeneron Pharmaceuticals, Inc., 7:26-cv-06026

Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). 1 case in that period is closed and not listed. Coverage of court records is not complete, and shareholder derivative suits are not included.

8 approvals or clearances and 1 recall recorded by the FDA for this company and its listed subsidiaries.

Approvals and clearances

• Aug 19PasatruDrug approval · Biologic approved. Active ingredient: Garetosmab-Grts
• Apr 22DupixentDrug approval · New use approved (efficacy supplement). Active ingredient: Dupilumab
• Apr 2Eylea HDDrug approval · New use approved (efficacy supplement). Active ingredient: Aflibercept
• Feb 23DupixentDrug approval · New use approved (efficacy supplement). Active ingredient: Dupilumab
• Nov 19Eylea HDDrug approval · New use approved (efficacy supplement). Active ingredient: Aflibercept
• Oct 29LibtayoDrug approval · New use approved (efficacy supplement). Active ingredient: Cemiplimab-Rwlc
• Oct 9PraluentDrug approval · New use approved (efficacy supplement). Active ingredient: Alirocumab
• Oct 8LibtayoDrug approval · New use approved (efficacy supplement). Active ingredient: Cemiplimab-Rwlc

Recalls

• Jul 28Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pha…Class II · Ongoing · Lack of Assurance of Sterility

From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.

29 certified in FY2026 Q3, vs 61 a year earlier. 29 positions in total, median offered wage $155K a year.

Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.